Expression and mutation of H-ras in uterine cervical cancer

Gynecologic Oncology

Volumn 62, Issue 1, 1996, Pages 49-54

  Lee, Ju Hie ^a,d   Lee, Seon Kyung ^a   Yang, Moon Ho ^a   Ahmed, Mansoor M ^b   Mohiuddin, Mohammed ^b   Lee, Eun Young ^c  

^a Kyung Hee University Hospital   (South Korea)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Kyung Hee University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

EID: 0030200980     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0188     Document Type: Article

References (27)

1. 1. Yoo, K. Y., and Kim, D. H. Trends in mortality and morbidity of uterine cervix, female breast and ovarian cancer in korea, Seoul J. Med. 33(3), 175-181 (1992).
2. 2. Lorincz, A. T., Temple, G. F., Kurman, R. J., Jenson, A. B., and Lancaster, W. D. Oncogenic association of specific human papilloma virus types with cervical neoplasia, J. Int. Cancer Inst. 79, 671-677 (1987).
3. 3. Dipaolo, J. A., Woodworth, C. D. E., Pepescu, N. C., Notario, V., and Doniger, J. Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras, Oncogene 4, 395-399 (1989).
4. 4. Barbacid, M. Ras oncogene: Their role in neoplasia, Eur. J. Clin. Invest. 20, 225-235 (1990).
5. 5. Gulbis, B., and Galand, P. Immunodetection of the p21-ras products in human normal and preneoplastic tissues and solid tumors, Hum. Pathol. 24, 1271-1285 (1993).
6. 6. O'Brien, T. J., Bannon, G. A., Bard, D. S., Hardin, J. W., and Quirk, J. G. Expression of the ras oncogene in gynecologic tumors, Am. J. Obstet. Gynecol. 160, 344-352 (1989).
7. 7. McGrath, J. P., Capon, D. J., Goeddel, D. V., and Levinson, A. D. Comparative biochemical properties of normal and activated human ras p21 protein, Nature 310, 644-649 (1984).
8. 8. Riou, G., Barrois, M., Sheng, Z.-M., Duvillard, P., and Lhomme, C. Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers, Oncogene 3, 329-333 (1988).
9. 9. Van Le, L., Stoerker, J., Rinehart, C. A., and Fowler, W. C. H-ras codon 12 mutations in cervical dysplasia, Gynecol. Oncol. 49, 181-184 (1993).
10. 10. Mansoor, A. M., Bharadwaj, T. P. R., Sethuraman, S., Chandy, M., Pushpa, V., Kamada, N., and Murthy, P. B. K. Analysis of karyotype, SCE, and point mutation of RAS oncogen in Indian MDS patients, Cancer Genet. Cytogenet. 65, 12-20 (1993).
11. 11. Kwok, S., and Higuchi, R. Avoiding false positives with PCR, Nature 339, 237-238 (1989).
12. 12. Nowell, P. Mechanism of tumor progression, Cancer Res. 46, 2203-2207 (1986).
13. 13. Thor, A., Hand, P. H., Wunderlich, D., Caruso, A., Muraro, R., and Schlom, J. Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases, Nature 311, 562-565 (1984).
14. 14. Viola, M., Fromowitz, F., Oravez, S., Deb, S., Finkel, G., Lundy, J., Hand, P., Thor, A., and Schlom, J. Expression of ras oncogene p21 in prostate cancer, N. Engl. J. Med. 314, 133-137 (1986).
15. 15. Der, C. J., and Cooper, G. M. Altered gene products are associated with activation of cellular ras-K genes in human lung and colon carcinomas, Cell 32, 201-208 (1983).
16. 16. Storey, A., Pim, D., Murray, A., Osborn, K., Banks, L., and Crawford, L. Comparison of the in-vitro transforming activities of human virus types, EMBO J. 7, 1815-1820 (1988).
17. 17. Pinion, S., Kennedy, J. H., Miller, R. W., and MacLean, A. B. Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of the cervix, Lancet 337, 819-820 (1991).
18. 18. Sagae, S., Kudo, R., Kuzumaki, N., Hisada, T., Mugikura, Y., Nihei, T., Takeda, T., and Hashimoto, M. Ras oncogene expression and progression in intraepithelial neoplasia of the uterine cervix, Cancer 66, 295-301 (1990).
19. 19. Sagae, S., Kuzumaki, N., Hisada, T., Mugikura, Y., Kudo, R., and Hashimoto, M. Ras oncogene expression and prognosis of invasive squamous cell carcinomas of the uterine cervix, Cancer 63, 1577-1582 (1989).
20. 20. Symonds, R. P., Habeshaw, T., Paul, D. J., Darling, K. A., Burnett, R. A., Sotsiou, F., Linardopoulos, S., and Spandidos, D. A. No correlation between ras, c-myc and c-jun protooncogene expression and prognosis in advanced carcinoma of cervix, Eur. J. Cancer 28A, 1615-1617 (1992).
21. 21. Willis, G., Jennings, B., Ball, R. Y., New, N. E., and Gibson, I. Analysis of ras point mutations and human papillomavirus 16 and 18 in cervical carcinomata and their metastases, Gynecol Oncol. 49, 359-364 (1993).
22. 22. Wilczynski, S. P., Cook, N., and Srivatsan, E. S. Alterations of ras oncogenes in cervical cancers, Lab. Invest. 70A, 408 (1992).
23. 23. Yokota, J., Tsukada, Y., Nakajima, T., Gotoh, M., Shimosato, Y., Mori, N., Tsunokawa, Y., Sugimura, T., and Terada, M. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix, Cancer Res. 49, 3598-3601 (1989).
24. 24. Stacey, D. W., and Kung, H. F. Transformation of NIH3T3 cells by microinjection of Ha ras p21 protein, Nature 310, 508-511 (1984).
25. 25. Schwab, M., Alitalo, K., Varmus, H. E., Bishop, J. M., and George, D. A cellular oncogene (c-Ki-ras) is amplified, overexpressed and located within karyotypic abnormalities in mouse adrenocortical tumor cells, Nature 303, 497-501 (1983).
26. 26. Hayashi, Y., Hachisuga, T., Iwasaka, T., Fukuda, K., Okuma, Y., Yokoyama, M., and Sugimori, H. Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement, Gynecol. Oncol. 40, 147-151 (1991).
27. 27. Ito, K., Sasano, H., Ozawa, N., Sato, S., and Yajima, A. K-ras point mutation and immunolocalization of EGFR, c-myc and c-erB-2 oncogene products in human endometrial and cervical adenocarcinoma, Lab. Invest. 66, 65A (1992).